T
Tomasz Brzostek
Researcher at Jagiellonian University Medical College
Publications - 86
Citations - 2755
Tomasz Brzostek is an academic researcher from Jagiellonian University Medical College. The author has contributed to research in topics: Health care & Patient safety. The author has an hindex of 13, co-authored 84 publications receiving 2348 citations. Previous affiliations of Tomasz Brzostek include New York Academy of Medicine & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Perception of Palliative Care and Euthanasia Among Recently Graduated and Experienced Nurses
TL;DR: Self-assessment of the understanding of these terms, recognition of clinical cases, potential acceptability of euthanasia, and an evaluation of attitudes towards palliative care and euthanasia among recent university bachelor degree graduates and experienced nurses in Poland were high.
Journal ArticleDOI
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.
TL;DR: Tofacitinib has been shown to reduce symptoms of RA and improve the quality of life in the analyzed groups of patients and was the first JAK inhibitor approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in the RA therapy, thus providing a useful alternative treatment strategy.
Journal ArticleDOI
Coffee consumption and colorectal cancer risk: a dose-response meta-analysis on prospective cohort studies.
TL;DR: The association between coffee consumption and CRC risk is controversial and should be clarified in further cohort studies.
Journal ArticleDOI
How Factor Analysis Results May Change Due to Country Context.
TL;DR: How factor analysis results of a Practice Environment Scale of the Nursing Work Index (PES-NWI) translation changed due to country context is presented to consider contextual differences when using results to inform policy.
Journal ArticleDOI
New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
TL;DR: Baricitinib therapy reduces symptoms of RA and improves the quality of life, and administered at an approved dose of 2 or 4 mg once daily offers a novel and promising alternative to parenterally administered biologic drugs used in RA treatment.